Search Results - "HOLTICK, U"

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey by Zeiser, R, Burchert, A, Lengerke, C, Verbeek, M, Maas-Bauer, K, Metzelder, S K, Spoerl, S, Ditschkowski, M, Ecsedi, M, Sockel, K, Ayuk, F, Ajib, S, de Fontbrune, F S, Na, I-K, Penter, L, Holtick, U, Wolf, D, Schuler, E, Meyer, E, Apostolova, P, Bertz, H, Marks, R, Lübbert, M, Wäsch, R, Scheid, C, Stölzel, F, Ordemann, R, Bug, G, Kobbe, G, Negrin, R, Brune, M, Spyridonidis, A, Schmitt-Gräff, A, van der Velden, W, Huls, G, Mielke, S, Grigoleit, G U, Kuball, J, Flynn, R, Ihorst, G, Du, J, Blazar, B R, Arnold, R, Kröger, N, Passweg, J, Halter, J, Socié, G, Beelen, D, Peschel, C, Neubauer, A, Finke, J, Duyster, J, von Bubnoff, N

“…Despite major improvements in allogeneic hematopoietic cell transplantation over the past decades, corticosteroid-refractory (SR) acute (a) and chronic (c)…”
Get full text

Consistent FFP2-masking as part of reducing viral respiratory infections on medical wards for allogeneic hematopoietic stem cell transplantation by Richardson, T., Schütte, D., Feyer, K., Grass, L., Hallek, M., Scheid, C., Simon, F., Braun, T., Fürstenau, M., Gödel, P., Holtick, U.

“…Patients undergoing allogenic hematopoietic stem cell transplantation (allo-HSCT) are highly susceptible to infections. The consequent use of masks on wards…”
Get full text

Adverse environmental conditions are a risk factor for ocular GvHD after allogeneic hematopoietic stem cell transplantation by Steven, P., Faust, C., Holtick, U., Scheid, C., Tahmaz, V., Stern, M. E., Gehlsen, U.

Get full text

Insulin eye drops for severe refractory chronic ocular graft-versus-host disease by Tahmaz, V., Menghesha, L., Stern, M. E., Holtick, U., Scheid, C., Steven, P.

Get full text

Meibography and meibomian gland measurements in ocular graft-versus-host disease by Engel, L A, Wittig, S, Bock, F, Sauerbier, L, Scheid, C, Holtick, U, Chemnitz, J-M, Hallek, M, Cursiefen, C, Steven, P

“…Meibomian gland loss in ocular GvHD was described as a mechanism contributing to dry eye and severe damage to the ocular surface. Infrared images of upper…”
Get full text

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma—A Retrospective Multicenter Analysis by Richardson, T., Kobbe, G., Fenk, R., Schroeder, T., Crysandt, M., Neuerburg, C., Holderried, Tobias A.W., Schütte, D., Gödel, P., Hallek, M., Scheid, C., Holtick, U.

“…ABSTRACT A growing list of therapies available for patients with multiple myeloma (MM) results in deep response rates, but eventually almost all patients…”
Get full text

Impact of choice, timing, sequence and combination of broad-spectrum antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation by Farowski, F, Bücker, V, Vehreschild, J J, Biehl, L, Cruz-Aguilar, R, Scheid, C, Holtick, U, Jazmati, N, Wisplinghoff, H, Cornely, O A, Vehreschild, M J G T

“…Recent data link the incidence of intestinal GvHD (iGvHD) after allogeneic haematopoietic stem cell transplantation (aSCT) to exposure with…”
Get full text

U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease by Scarisbrick, J.J., Taylor, P., Holtick, U., Makar, Y., Douglas, K., Berlin, G., Juvonen, E., Marshall, S.

“…Summary Extracorporeal photopheresis (ECP) has been used for over 30 years in the treatment of erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years…”
Get full text

P10.01 Nutritional and immunometabolic measures for risk assessment in allogeneic hematopoietic stem cell transplantation by Thurisch, H, Althoff, K, Leitzke, S, Holtick, U, Scheid, C, Oganesian, S, Funk, M, Cordas dos Santos, D, von Bergwelt-Baildon, M, Theurich, S

“…BackgroundThe hematopoietic transplant comorbidity index (HTC-CI) has been developed to determine treatment-related morbidity following allogeneic…”
Get full text

S235: A TWO‐PART, SINGLE‐ AND TWO‐ARM RANDOMIZED, OPEN‐LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE S1P RECEPTOR MODULATOR KRP203 IN SUBJECTS WITH HEMATOLOGICAL MALIGNANCIES by dertschnig, S., finke, J., heim, D., schanz, U., holler, E., holtick, U., socié, G., teshima, T., bucher, C., passweg, J.

Get full text

OUTCOME DETERMINANTS OF COMMERCIAL CAR‐T CELL THERAPY FOR LARGE B‐CELL LYMPHOMA: RESULTS OF THE GLA/DRST REAL WORLD ANALYSIS by Dreger, P., Martus, P., Holtick, U., Ayuk, F., Wagner‐Drouet, E. M., Wulf, G., Marks, R., Penack, O., Koenecke, C., von Bonin, M., von Tresckow, B., Stelljes, M., Baldus, C., Vucinic, V., Mougiakakos, D., Topp, M., Wolff, D., Schroers, R., Schmitt, M., Schmitt, T., Lengerke, C., Thomas, S., Beelen, D. W., Bethge, W.

Get full text

Predicting survival using clinical risk scores and non-HLA immunogenetics by Balavarca, Y, Pearce, K, Norden, J, Collin, M, Jackson, G, Holler, E, Dressel, R, Kolb, H-J, Greinix, H, Socie, G, Toubert, A, Rocha, V, Gluckman, E, Hromadnikova, I, Sedlacek, P, Wolff, D, Holtick, U, Dickinson, A, Bickeböller, H

“…Previous studies of non-histocompatibility leukocyte antigen (HLA) gene single-nucleotide polymorphisms (SNPs) on subgroups of patients undergoing allogeneic…”
Get full text

P1184: PHASE I TRIAL OF MB‐CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B‐CELL NON‐HODGKIN LYMPHOMA: 2 YEAR FOLLOW‐UP REPORT by Borchmann, P., Lohneis, A., Gödel, P., Balke‐Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Hanssens, L., Zadoyan, G., Friedrichs, B., Assenmacher, M., Bürger, I., Schneider, D., Overstijns, T., Scheid, C., Holtick, U., Miltenyi, S., Hallek, M.

Get full text

P1448: LONG‐TERM SURVIVORS AFTER FAILURE OF CAR‐T CELL THERAPY FOR R/R LARGE B‐CELL LYMPHOMA (LBCL): A GLA/DRST STUDY by Derigs, P., Bethge, W., Holtick, U., Tresckow, B., Ayuk, F., Penack, O., Vucinic, V., Bonin, M., Baldus, C., Mougiakakos, D., Wulf, G., Schnetzke, U., Stelljes, M., Thomas, S., Schroers, R., Kroeger, N., Dreger, P.

Get full text

STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis by HOLTICK, U, VOCKERODT, M, TRÜMPER, L, KUBE, D, PINKERT, D, SCHOOF, N, STÜRZENHOFECKER, B, KUSSEBI, N, LAUBER, K, WESSELBORG, S, LÖFFLER, D, HORN, F

“…Classical Hodgkin lymphoma (cHL) is a distinct malignancy of the immune system. Despite the progress made in the understanding of the biology of cHL, the…”
Get full text

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER CD19 CAR T‐CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE by Bücklein, V., Perez, A., Iacoboni, G., Rejeski, K., Holtick, U., Penack, O., Kharboutli, S., Blumenberg, V., Ackermann, J., Frölich, L., Johnson, G., Patel, K., Arciola, B., Schmidt, C., Albanyan, O., Gödel, P., Hoster, E., Bullinger, L., Mackensen, A., Locke, F., Bergwelt, M., Barba, P., Jain, M. D., Subklewe, M.

Get full text

Allogeneic haematopoietic stem cell transplantation - an overview by Holtick, U, Chemnitz, J M, Hallek, M, Scheid, C

“…Allogeneic haematopoietic stem cell transplantation is an effective treatment option for chemotherapy-refractory or relapsed haematological malignancies such…”
Get more information

Nonmyeloablative allogeneic stem cell transplantation for chronic lymphocytic leukaemia offers the possibility of disease control with minimal morbidity and mortality—a single institution experience by Chakupurakal, G., Leitzke, S., Langerbeins, P., Schiller, J., Schneider, P. M., Holtick, U., Shimabukuro-Vornhagen, A., Theurich, S., Chemnitz, J., Hallek, M., von Bergwelt-Baildon, M., Scheid, C.

“…Allogeneic stem cell transplantation is a treatment option for patients with poor risk CLL. We conducted a retrospective analysis of all CLL patients…”
Get full text

Impact of genomic risk factors on survival after haematopoietic stem cell transplantation for patients with acute leukaemia by Pearce, K. F., Balavarca, Y., Norden, J., Jackson, G., Holler, E., Dressel, R., Greinix, H., Toubert, A., Gluckman, E., Hromadnikova, I., Sedlacek, P., Wolff, D., Holtick, U., Bickeböller, H., Dickinson, A. M.

“…Summary The EBMT risk score is an established tool successfully used in the prognosis of survival post‐HSCT and is applicable for a range of haematological…”
Get full text

Haploidentical bone marrow transplantation with post-grafting cyclophosphamide: multicenter experience with an alternative salvage strategy by Tuve, S, Gayoso, J, Scheid, C, Radke, J, Kiani, A, Serrano, D, Platzbecker, U, Rodríguez-Macías, G, Wermke, M, Holtick, U, Balsalobre, P, Middeke, J M, Shayegi, N, Chemnitz, J M, Krause, A, Gruner, N, Füssel, M, Schetelig, J, Thiede, C, Ehninger, G, Hallek, M, Díez-Martín, J L, Bornhäuser, M

Get full text